Meiji Yasuda Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $260K | Buy |
417
+13
| +3% | +$8.85K | 0.01% | 507 |
|
|
2026
Q1 | $312K | Sell |
404
-98
| -20% | -$75K | 0.02% | 426 |
|
|
2025
Q4 | $387K | Sell |
502
-197
| -28% | -$134K | 0.02% | 381 |
|
|
2025
Q3 | $393K | Sell |
699
-60
| -8% | -$33.9K | 0.02% | 385 |
|
|
2025
Q2 | $398K | Sell |
759
-1,550
| -67% | -$865K | 0.02% | 374 |
|
|
2025
Q1 | $1.46M | Sell |
2,309
-26
| -1% | -$17.9K | 0.06% | 273 |
|
|
2024
Q4 | $1.66M | Sell |
2,335
-35
| -1% | -$29.4K | 0.06% | 249 |
|
|
2024
Q3 | $2.49M | Buy |
2,370
+56
| +2% | +$62.3K | 0.09% | 211 |
|
|
2024
Q2 | $2.43M | Buy |
2,314
+119
| +5% | +$115K | 0.1% | 196 |
|
|
2024
Q1 | $2.11M | Sell |
2,195
-1,702
| -44% | -$1.62M | 0.09% | 211 |
|
|
2023
Q4 | $3.42M | Sell |
3,897
-56
| -1% | -$46.1K | 0.15% | 175 |
|
|
2023
Q3 | $3.25M | Buy |
3,953
+1,862
| +89% | +$1.46M | 0.15% | 183 |
|
|
2023
Q2 | $1.5M | Buy |
2,091
+5
| +0.2% | +$3.85K | 0.08% | 244 |
|
|
2023
Q1 | $1.71M | Sell |
2,086
-2,010
| -49% | -$1.52M | 0.09% | 225 |
|
|
2022
Q4 | $2.96M | Sell |
4,096
-1,944
| -32% | -$1.43M | 0.14% | 191 |
|
|
2022
Q3 | $4.16M | Sell |
6,040
-300
| -5% | -$189K | 0.24% | 127 |
|
|
2022
Q2 | $3.75M | Sell |
6,340
-1,780
| -22% | -$1.16M | 0.22% | 141 |
|
|
2022
Q1 | $5.67M | Sell |
8,120
-237
| -3% | -$150K | 0.31% | 86 |
|
|
2021
Q4 | $5.28M | Buy |
8,357
+188
| +2% | +$116K | 0.33% | 79 |
|
|
2021
Q3 | $4.94M | Sell |
8,169
-252
| -3% | -$156K | 0.35% | 75 |
|
|
2021
Q2 | $4.7M | Buy |
8,421
+40
| +0.5% | +$20.3K | 0.22% | 97 |
|
|
2021
Q1 | $3.96M | Buy |
8,381
+570
| +7% | +$278K | 0.29% | 92 |
|
|
2020
Q4 | $3.77M | Buy |
7,811
+1,294
| +20% | +$699K | 0.37% | 70 |
|
|
2020
Q3 | $3.65M | Sell |
6,517
-780
| -11% | -$473K | 0.4% | 65 |
|
|
2020
Q2 | $4.55M | Buy |
7,297
+5,820
| +394% | +$3.3M | 0.43% | 55 |
|
|
2020
Q1 | $721K | Sell |
1,477
-800
| -35% | -$330K | 0.14% | 138 |
|
|
2019
Q4 | $855K | Buy |
2,277
+290
| +15% | +$97.6K | 0.07% | 266 |
|
|
2019
Q3 | $551K | Sell |
1,987
-100
| -5% | -$29.6K | 0.04% | 340 |
|
|
2019
Q2 | $653K | Sell |
2,087
-757
| -27% | -$252K | 0.05% | 325 |
|
|
2019
Q1 | $1.17M | Sell |
2,844
-20
| -0.7% | -$8.24K | 0.1% | 221 |
|
|
2018
Q4 | $1.07M | Sell |
2,864
-13
| -0.5% | -$4.76K | 0.1% | 218 |
|
|
2018
Q3 | $1.16M | Buy |
2,877
+1,100
| +62% | +$419K | 0.09% | 226 |
|
|
2018
Q2 | $613K | Hold |
1,777
| – | – | 0.05% | 331 |
|
|
2018
Q1 | $612K | Buy |
1,777
+100
| +6% | +$34.8K | 0.06% | 324 |
|
|
2017
Q4 | $630K | Sell |
1,677
-300
| -15% | -$122K | 0.06% | 328 |
|
|
2017
Q3 | $884K | Buy |
1,977
+300
| +18% | +$143K | 0.09% | 249 |
|
|
2017
Q2 | $824K | Hold |
1,677
| – | – | 0.08% | 257 |
|
|
2017
Q1 | $650K | Sell |
1,677
-300
| -15% | -$111K | 0.07% | 294 |
|
|
2016
Q4 | $726K | Buy |
1,977
+675
| +52% | +$257K | 0.08% | 263 |
|
|
2016
Q3 | $523K | Sell |
1,302
-330
| -20% | -$132K | 0.06% | 305 |
|
|
2016
Q2 | $570K | Buy |
1,632
+780
| +92% | +$300K | 0.08% | 257 |
|
|
2016
Q1 | $307K | Buy |
852
+10
| +1% | +$4.12K | 0.07% | 270 |
|
|
2015
Q4 | $457K | Buy |
842
+145
| +21% | +$78.6K | 0.1% | 197 |
|
|
2015
Q3 | $324K | Sell |
697
-30
| -4% | -$16.1K | 0.08% | 255 |
|
|
2015
Q2 | $371K | Sell |
727
-150
| -17% | -$73.2K | 0.09% | 238 |
|
|
2015
Q1 | $396K | Hold |
877
| – | – | 0.1% | 222 |
|
|
2014
Q4 | $360K | Sell |
877
-80
| -8% | -$31.5K | 0.09% | 256 |
|
|
2014
Q3 | $345K | Sell |
957
-410
| -30% | -$137K | 0.08% | 259 |
|
|
2014
Q2 | $386K | Buy |
1,367
+77
| +6% | +$22.8K | 0.08% | 241 |
|
|
2014
Q1 | $387K | Buy |
1,290
+290
| +29% | +$89.3K | 0.08% | 233 |
|
|
2013
Q4 | $275K | Buy |
+1,000
| New | +$288K | 0.06% | 302 |
|
Other funds holding REGN
Meiji Yasuda Asset Management's REGN Position: Q2 2026 in Review
Meiji Yasuda Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 3.2% in Q2 2026, buying an estimated $8.85K and bringing the position to 417 shares worth $260K. The position accounts for 0.01% of the portfolio, ranked #507.
Meiji Yasuda Asset Management first reported a position in REGN in Q4 2013 and has held it in 51 quarters since. The position peaked at $5.67M in Q1 2022. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Meiji Yasuda Asset Management held 417 shares of Regeneron Pharmaceuticals worth $260K as of Q2 2026.
- Meiji Yasuda Asset Management bought 13 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.85K.
- Regeneron Pharmaceuticals made up 0.01% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #507 holding.
- Meiji Yasuda Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 51 quarters since.
- Meiji Yasuda Asset Management's Regeneron Pharmaceuticals position peaked at $5.67M in Q1 2022.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.